Form 8-K - Current report:
SEC Accession No. 0001213900-24-114021
Filing Date
2024-12-31
Accepted
2024-12-31 16:31:26
Documents
14
Period of Report
2024-12-23
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226496-8k_cerotherap.htm   iXBRL 8-K 32275
  Complete submission text file 0001213900-24-114021.txt   252577

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cero-20241223.xsd EX-101.SCH 3798
3 XBRL LABEL FILE cero-20241223_lab.xml EX-101.LAB 36817
4 XBRL PRESENTATION FILE cero-20241223_pre.xml EX-101.PRE 25297
5 XBRL DEFINITION FILE cero-20241223_def.xml EX-101.DEF 26673
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0226496-8k_cerotherap_htm.xml XML 5942
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 241593375
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)